Polatuzumab vedotin (Polivy®). HTA ID: 22043

Assessment Status Awaiting response from Applicant
HTA ID 22043
Drug Polatuzumab vedotin
Brand Polivy®
Indication In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Assessment Process
Rapid review commissioned 27/06/2022
Rapid review completed 27/07/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/08/2022
Pre-submission consultation with Applicant 08/11/2022
Full submission received from Applicant 26/01/2023
Preliminary review sent to Applicant 20/07/2023